

Substitute for form 1449A-B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/849,592		
JAN 30 2003 (use as many sheets as necessary)		Filing Date	May 4, 2001		
		First Named Inventor	Edward T. W. i		
		Group Art Unit	1631		
		Examiner Name	Unassigned		
		Attorney Docket Number	407T-976201US		
		Date Submitted	January 2, 2003		



U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
My	01	4,016,100		Suzuki et al.	04-05-1977
	02	4,091,090		Sipos	05-23-1978
	03	4,348,384		Horikoshi et al.	09-07-1982
	04	5,126,327		Takeuchi	06-1992
	05	5,480,869		Wei et al.	01-02-1996
	06	5,482,930		Wei et al.	01-09-1996
My	07	5,514,670		Friedman et al.	05-07-1996

RECEIVED

JAN 31 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
My	08	GB	2193891			08-14-1987
My	09	WO	97/47316			12-18-1997

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
My	12	Dooley et al. (1996) "New, Highly Active Orphanin Receptor Ligands Identified Using Combinatorial Libraries," poster abstract from the 27 th Meeting of the International Narcotics Research Conference, abstract TU13, Long Beach, California, 1996.				
	11	Hadley et al. (1996) "Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists," Pigment Cell Res., pp. 213-234.				
	12	Henderson and McKnight (1997) "The Orphan Opioid Receptor and Its Endogenous Ligand - Nociceptin/Orphanin FG," Trends in Pharmacological Sciences, 18, pp. 293-300.				
	13	Ollmann et al. (1997) "Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein," Science, 278, pp. 135-138.				
	14	Quillan and Sadee (1997) "Dynorphin Peptides: Antagonists of Melanocortin Receptors," Pharmaceutical Research, 14:6, pp. 713-719.				
My	15	Siegrist and Eberle (1995) Melanocortins and Their Implication in Melanoma," TEM, 6:4, pp. 115-120.				

Examiner Signature	<i>My</i>	Date Considered	<i>01/04</i>
--------------------	-----------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/849,592
JAN 30 2003 (use as many sheets as necessary)		Filing Date	May 4, 2001
		First Named Inventor	Edward T. W. I
		Group Art Unit	1631
		Examiner Name	Unassigned
		Attorney Docket Number	407T-976201US
		Date Submitted	January 2, 2003

16	Siegrist et al. (1997) "Interactions of α -Melanotropin and Agouti on B16 Melanoma Cells: Evidence for Inverse Agonism of Agouti," J. Recept. Signal. Transduct. Res., 17, pp. 75-98.
17	Berge et al. (1977) "Pharmaceutical Salts," J. Pharm. Sci., 66:1, pp. 1-19.
18	Yang et al. (1997) "Effects of Recombinant Agouti-Signaling Protein on Melanocortin Action," Mol. Endocrinol., 11, pp. 274-2880.
19	Sawyer et al. (1989) Peptide Research, 2(1), 140-146.
20	Thomas et al. (1995) Peptides, 16(3), 547-50.
21	Vlasov et al. (1996) Proc. Eur. Pept. Symp., 24 th , Meeting Date 1996, 877-878. Editors: Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientific, Kingswinford, UK.
22	Dowdy et al. (1995) Photodermatol., Photoimmunol. Photomed., 11(4), 143-8
23	Zhang et al. (1996) Chin. Med. Sci. J. 11(2)63-68.

RECEIVED

JAN 31 2003

TECH CENTER 1600/29

Examiner Signature	<i>W. B. Ross</i>	Date Considered	<i>01/04</i>
-----------------------	-------------------	--------------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.